Objectives: To determine if the intravenous co-administration of equal volumes of lidocaine and nalbuphine, with undiluted normal saline, prevents injection pain caused by nalbuphine.

Methods: Eighty adult patients who were scheduled for minor surgeries under general anesthesia delivered via a laryngeal mask airway (LMA) were enrolled in this prospective, randomized, single-blind clinical trial. In the saline group (control) (n = 40), 1 mL (10 mg) nalbuphine was diluted with 9 mL normal saline. In the lidocaine group (experimental) (n = 40), 1 mL (10 mg) nalbuphine was diluted with 1 mL lidocaine (20 mg). The two respective nalbuphine solutions were injected into the cephalic vein at a rate of 20 mL/minute (0.33 mL/second). Pain scores were categorized into five grades. Pain responses upon intravenous injection of nalbuphine, site of cannulation, size of the catheter, and hemodynamic responses to nalbuphine were also recorded.

Results: Overall, the median pain score of patients in the lidocaine group was lower than that of the saline group (p < 0.001). In addition, the incidence of injection pain was lower in the lidocaine group than the saline group (2.5% vs. 30%, p = 0.001).

Conclusion: A solution of equal volumes of lidocaine and nalbuphine can decrease intravenous nalbuphine-induced injection pain.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aat.2011.11.009DOI Listing

Publication Analysis

Top Keywords

injection pain
16
equal volumes
12
saline group
12
lidocaine group
12
nalbuphine
8
saline prevents
8
nalbuphine-induced injection
8
volumes lidocaine
8
lidocaine nalbuphine
8
normal saline
8

Similar Publications

Background: Pain management is a critical part of treatment in patients with chest trauma. Opioids and nonsteroidal anti-inflammatory drugs have been the most commonly used medications. However, their side effects have drawn attention to other medications.

View Article and Find Full Text PDF

Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?

Clin Endocrinol (Oxf)

December 2024

Departments of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospital NHS Trust, Leeds, UK.

With the current therapeutic modalities available to endocrinologists, control of GH and IGF-I is now possible in almost all patients with acromegaly with multi-modality therapy. Despite biochemical control of GH and IGF-I, patients with acromegaly continue to experience impaired quality of life. Although there are likely multiple factors contributing to this dissatisfaction with current medical therapies, in particular the widely utilised injectable long-acting somatostatin receptor ligands (iSRL), is a contributor.

View Article and Find Full Text PDF

Osteoarthritis (OA) of the foot and ankle is prevalent and often debilitating, necessitating effective treatment options. This study evaluates the analgesic efficacy of corticosteroid injections in individual foot and ankle joints. Stepping Hill Hospital conducted a retrospective audit of 166 patients who received guided corticosteroid injections.

View Article and Find Full Text PDF

Background: Pain and inflammation are closely associated with rheumatoid arthritis (RA), which affects the bones and joints.

Aim: While there are a number of therapeutic options for arthritis, their side effects restrict their use and encourage the search for alternative, natural remedies.

Methods: In male rats, we examined the anti-inflammatory and anti-arthritic properties of venom (NHV).

View Article and Find Full Text PDF

Background: This study aimed to evaluate the diagnostic performance of ESAT6-CFP10 (EC) skin test in healthy population and determine the factors influencing the booster effect.

Methods: We conducted a randomized, double-blind, parallel controlled trial in healthy population. The experiment was divided into two stages.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!